Section overview: Hyperglycemia in ACS

Slides:



Advertisements
Similar presentations
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Advertisements

Aggressive Hyperglycemia Management. Significant hospital hyperglycemia requires close follow-up Previously diagnosed diabetes and elevated A1C Without.
Henry C. Ginsberg, MD College of Physicians & Surgeons, Columbia University, New York For The ACCORD Study Group.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Canadian Diabetes Association 2013 Clinical Practice Guidelines Targets for Glycemic Control Chapter 8 S. Ali Imran, Rémi Rabasa-Lhoret, Stuart Ross.
Diabetes Trials Unit University of Oxford WebSite: Lipids in Diabetes Study.
ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Individualizing Targets and Tactics for High- Risk Patients With Type 2 Diabetes Practical lessons from ACCORD and other cardiovascular trials Featured.
Joint Effects of Routine Blood Pressure Lowering and Intensive Glucose Control ADVANCE Adapted from EASD 2008.
Session II: Glycemic control, when the lower is not the better Strict glycemic control and cardiovascular diseases Stefano Genovese Diabetologia e Malattie.
1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.
William C. Cushman, MD, FACP, FAHA Veterans Affairs Medical Center, Memphis, TN For The ACCORD Study Group.
Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)
Glycemic Control: When the Lower is Not the “Better”?
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
A Diabetes Outcome Progression Trial
An initiative of South Asian Federation of Endocrine Societies (SAFES)
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
Results from ASCOT-BPLA: Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm VBWG.
R1. 이정미 / prof. 이상열. INTRODUCTION Type 2 diabetes is a major risk factor for cardiovascular disease The presence of both type 2 diabetes and.
Summary of “A randomized trial of standard versus intensive blood-pressure control” The SPRINT Research Group, NEJM, DOI: /NEJMoa Downloaded.
Clinical Outcomes with Newer Antihyperglycemic Agents
Dr John Cox Diabetes in Primary Care Conference Cork
Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Blood Pressure and Lipid Trials: Rationale, Importance and Design
Clinical Outcomes with Newer Antihyperglycemic Agents
Nephrology Journal Club The SPRINT Trial Parker Gregg
The ACCORD Trial: Review of Design and Results
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
ACCORD Design and Baseline Characteristics
Hypertension in the Post SPRINT era
Hypertension JNC VIII Guidelines.
Baseline characteristics and effectiveness results
Vanguard Phase Results for the Blood Pressure Component
HOPE: Heart Outcomes Prevention Evaluation study
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
Pravastatin in Elderly Individuals at Risk of Vascular Disease
The Anglo Scandinavian Cardiac Outcomes Trial
PS Sever, PM Rothwell, SC Howard, JE Dobson, B Dahlöf,
AIM HIGH Niacin plus Statin to prevent vascular events
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Diabetes Health Status Report
The following slides highlight a presentation at the Hotline Session of the European Society of Cardiology Annual Congress, September 3-7, 2005 in Stockholm,
AIM-HIGH Niacin Plus Statin to Prevent Vascular Events
FATS- Familial Atherosclerosis Treatment Study
RAAS Blockade: Focus on ACEI
Systolic Blood Pressure Intervention Trial (SPRINT)
Progress and Promise in RAAS Blockade
Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)
The following slides highlight a report on a presentation at the Late-breaking Trials Session and a Satellite Symposium of the American Heart Association.
Section I: RAS manipulation C. Update on clinical trials in CAD
Sodium-glucose co-transporter 2 (SGLT2) inhibitors work by blocking the reabsorption of filtered glucose in the kidneys. This leads to glucosuria and improved.
The Hypertension in the Very Elderly Trial (HYVET)
Effects of Intensive Blood Pressure Control on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes.
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Section overview: Cardiometabolic risk reduction
Table of Contents Why Do We Treat Hypertension? Recommendation 5
These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.
LRC-CPPT and MRFIT Content Points:
The following slides are from a Cardiology Scientific Update in which Dr. Gordon Moe reported and discussed an original presentation by Drs. Bjorn Dahlof,
These slides highlight a report from a Hotline Session and a Satellite symposium held at the European Society of Cardiology Congress, 2003 in Vienna Austria,
The following slides highlight a report by Dr
The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Section 6: Update on lipid treatment guidelines
Many post-MI patients are not receiving optimal therapy
Presentation transcript:

Section overview: Hyperglycemia in ACS

ACC/AHA UA/NSTEMI and STEMI guidelines: Post-discharge management of patients with diabetes Secondary prevention guidelines include recommendations for specific interventions directed at patients with diabetes (class of recommendation and LOE): Initiate lifestyle and pharmacotherapy to achieve near-normal A1C of <7%. (I B) Begin vigorous modification of other risk factors (eg, physical activity, weight management, blood pressure [BP] control, and cholesterol management according to guidelines recommendation). (I B) Coordinate diabetic care with the patient’s primary care physician (PCP) or endocrinologist. (I C) Abbreviations: ACC = American College of Cardiology NSTEMI = non-ST-elevation myocardial infarction UA = unstable angina

DIGAMI 2 post-hoc analysis: Glucose-lowering drugs and long-term outcome Mellbin et al followed 1181 DIGAMI 2 participants who were discharged from hospital following AMI treatment. The median follow-up was 2.1 years. At each follow-up visit, information was obtained on ongoing glucose-lowering therapy. There was no difference in mortality among insulin, metformin, and sulfonylureas. However, there was an increased risk for nonfatal MI or stroke with insulin.

Observational studies of insulin and clinical outcomes The Euro Heart Survey on Diabetes and the Heart in a multi-center registry conducted in 25 European countries. The present report concerns the cohort (n = 1281) with diabetes (established diagnosis or on glucose-lowering drugs) and coronary artery disease (CAD). In patients treated with insulin only (n = 378) compared with those treated with oral agents only (n = 675), there was a higher risk of all-cause mortality (HR 2.23, 95% CI 1.24-4.03) and a nonsignificant trend for higher risk of CV events (HR 1.27, 95% CI 0.85-1.87). However, these findings were not confirmed in a second, larger observational study. Engel-Nitz et al conducted a retrospective medical records study of 342,692 enrollees in a US managed care plan. The OR for a CV event in those receiving insulin (n = 14,167) compared with those receiving oral agents (n = 328,077) was 0.66 (95% CI 0.61-0.71).

Insulin and clinical outcomes: Limitations of available data Limitations of the 3 trials discussed in the previous slides include their retrospective design, the lack of randomization of study drugs, and the lack of adjustment for underlying disease severity (ie, was insulin reserved for sicker patients?). Thus, these trials can be considered hypothesis-generating only.

ACCORD, ADVANCE: Addressing 3 key questions The Action to Control Cardiovascular Risk in Diabetes (ACCORD) and Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trials are designed to provide insight into a common set of questions relating to reduction of CV disease events in high-risk patients with T2DM. Both trials are randomized and controlled. Each also has a factorial design. Abbreviations: HDL-C = high-density lipoprotein cholesterol LDL-C = low-density lipoprotein cholesterol TG = triglyceride

ACCORD: Study design ACCORD was designed to test 3 different medical strategies: Intensive (A1C <6%) vs standard (A1C 7%-7.9%) glycemic control. Study investigators could use all currently available glucose-lowering drugs using algorithms developed for the trial. Intensive (systolic BP [SBP] <120 mm Hg) vs standard (SBP <140 mm Hg) BP control. Multifactorial lipid modulation with statin plus fibrate vs LDL-C lowering alone with a statin. Study subjects (N = 10,251) had T2DM and either confirmed CV disease or combinations of risk factors and/or conditions suggesting a high likelihood of CV disease. The primary outcome was time to first occurrence of CV death, MI, or stroke.

ADVANCE: Study design ADVANCE was designed to test 2 different strategies: Intensive (A1C 6.5% or lower) vs standard (guidelines-based) glycemic control. The intensive arm was based on a modified-release formulation of the sulfonylurea gliclazide. Those participants in the other arm continued with their usual glucose-lowering regimens except gliclazide. Perindopril 4 mg plus indapamide 1.25 mg vs placebo. Other antihypertensive medications, with the exception of angiotensin-converting enzyme inhibitors (ACEIs) and thiazide diuretics, were permitted. Study subjects (N = 11,140) had T2DM, were 55 years of age or older, and had either a history of CV disease or at least 1 other CV risk factor. The macrovascular primary outcome was a composite of CV death, MI, and stroke. The microvascular primary outcome was a composite of new/worsening nephropathy (development of macroalbuminuria, doubling of serum creatinine to a level of at least 2.26 mg/dL, need for renal replacement, or death due to renal disease) or retinopathy (development of proliferative retinopathy, macular edema, or diabetes-related blindness, or retinal photocoagulation therapy).

ACCORD: Treatment effects on glucose control At 1 year, median A1C levels were 6.4% and 7.5% in the intensive- and standard-therapy groups, respectively. The difference between the two groups was maintained for the duration of the study. The rate of hypoglycemic episodes requiring medical assistance was 3.1% per year and 1.0% per year, respectively.

ACCORD: Treatment effect on primary outcome The primary outcome occurred in 6.9% and 7.2% of patients in the intensive and standard groups, respectively; HR 0.90 (95% CI 0.78-1.04), P = 0.16.

ACCORD: Treatment effect on all-cause mortality The all-cause mortality rate was 5.0% and 4.0% in the intensive and standard groups, respectively; HR 1.22 (1.01-1.46), P = 0.04. CV death followed a similar trend: 2.6% and 1.8%, respectively; HR 1.35 (1.04-1.76), P = 0.02 (data not shown). However, nonfatal MI was lower in the intensive group: 3.6% vs 4.6%; HR 0.76 (0.62-0.92), P = 0.004 (data not shown). Nonfatal stroke and congestive HF did not differ significantly between the groups (data not shown).

ADVANCE: Treatment effect on glucose control After a median of 5 years, mean A1C values were 6.5% and 7.3% in the intensive and standard treatment groups, respectively. Severe hypoglycemia occurred in 2.7% and 1.5%, respectively.

ADVANCE: Treatment effect on primary macrovascular outcome The macrovascular primary outcome occurred in 10.0% and 10.6% of the intensive and standard groups, respectively; HR 0.94 (0.84-1.06), P = 0.32. The combined primary outcome occurred in 18.1% and 20.0% of patients, respectively; HR 0.90 (0.82-0.98), P = 0.01 (data not shown). The microvascular primary outcome occurred in 9.4% and 10.9% of patients, respectively; HR 0.86 (0.77-0.97), P = 0.01 (data not shown).

ADVANCE: Treatment effect on all-cause mortality The all-cause mortality rate was 8.9% and 9.6% in the intensive and standard groups, respectively, a nonsignificant difference; HR 0.93 (0.83-1.06). Secondary CV outcomes also did not differ significantly between the groups, including CV death, nonfatal MI, nonfatal stroke, and HF (data not shown).

VADT: Effect of intensive therapy on A1C The Veterans Affairs Diabetes Trial (VADT) was designed to compare the effects of intensive vs standard glucose control on CV events in patients with T2DM. Subjects (n = 1791) with poorly controlled T2DM were randomized to receive either intensive or standard glucose control. Subjects with a BMI of 27 kg/m(2) or greater were placed on metformin and rosiglitazone; subjects with a BMI <27 kg/m(2) were started on glimepiride and rosiglitazone. Subjects in the intensive group were started on maximal dose; those in the standard group were started on one-half of the maximal dose. Insulin was given to subjects on a case-by-case basis. Mean age and time since T2DM diagnosis at baseline were 60.4 years and 11.5 years, respectively. Median follow-up was 5.6 years; longest was 7.5 years. Mean A1C value at baseline was 9.4% for both groups. At study end, median A1C values in the intensive and standard groups were 6.9% and 8.4%, respectively.

VADT: Effect of intensive therapy on time to major CV event The primary outcome was the time to first occurrence of a major CV event, a composite of myocardial infarction, stroke, CV death, congestive heart failure, surgery for vascular disease, inoperable coronary disease, and amputation for ischemic gangrene. This outcome occurred in 235 patients in the intensive group and in 264 patients in the standard group, which did not attain statistical significance.

ACCORD, ADVANCE, VADT: Long-term glycemic control in high-risk T2DM In confirmation of other studies, the ADVANCE results show that intensive glucose control adds incremental benefit over standard glucose control with regard to reduction in microvascular events. However, intensive glucose control does not significantly lower CV events in high-risk patients with T2DM. In an accompanying editorial, Robert G. Dluhy, MD, and Graham T. McMahon, MD, MMSc, write, “Clinicians caring for patients with diabetes should continue to focus on smoking cessation, dietary and exercise counseling, blood-pressure control, and providing aspirin and a statin to a greater extent than achieved even in the ADVANCE and ACCORD studies.”(1) Consensus is lacking on optimal long-term glucose targets, although in patients with diabetes who are at high-risk for CV events it would be prudent to set a goal A1C of approximately 7%. Consensus is also lacking on strategies for achieving and maintaining glucose targets. 1. Dluhy RG, McMahon GT. N Engl J Med. 2008;358:2630-33.

Post-discharge, long-term glycemic control: Summary While there is strong evidence that lowering glucose reduces risk of microvascular events, there is no consensus regarding its effect on macrovascular events, particularly following AMI. Pending results of ongoing clinical trials, decisions regarding glycemic targets for long-term control and the optimal regimens for achieving those targets will have to be based on clinical judgment.